Advertisement
JAZZ vs ROCK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and ROCK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAZZ’s FA Score shows that 0 FA rating(s) are green whileROCK’s FA Score has 0 green FA rating(s).
- JAZZ’s FA Score: 0 green, 5 red.
- ROCK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAZZ’s TA Score shows that 6 TA indicator(s) are bullish while ROCK’s TA Score has 4 bullish TA indicator(s).
- JAZZ’s TA Score: 6 bullish, 3 bearish.
- ROCK’s TA Score: 4 bullish, 3 bearish.
Price Growth
JAZZ (@Biotechnology) experienced а +2.90% price change this week, while ROCK (@Building Products) price change was +1.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.
The average weekly price growth across all stocks in the @Building Products industry was -0.62%. For the same industry, the average monthly price growth was +5.61%, and the average quarterly price growth was +3.73%.
Reported Earning Dates
JAZZ is expected to report earnings on Nov 05, 2025.
ROCK is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Biotechnology (+2.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Building Products (-0.62% weekly)The industry manufactures products used in the construction of residential and commercial buildings. The process involves using materials and other products, and processing them to create finished items such as doors, windows, light fittings, floor coverings, climate control products and other building components and home improvement products. Masco Corporation, Allegion PLC and Lennox International Inc. are major manufacturers of such products.
| JAZZ | ROCK | JAZZ / ROCK | |
| Capitalization | 6.8B | 2.45B | 277% |
| EBITDA | 1.25B | 179M | 698% |
| Gain YTD | -8.810 | 6.265 | -141% |
| P/E Ratio | 15.26 | 22.23 | 69% |
| Revenue | 4.07B | 1.38B | 295% |
| Total Cash | 2.57B | 99.4M | 2,588% |
| Total Debt | 5.42B | 46.3M | 11,706% |
JAZZ | ROCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 96 | 78 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 56 | 49 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JAZZ's Valuation (50) in the Pharmaceuticals Other industry is in the same range as ROCK (50) in the Metal Fabrication industry. This means that JAZZ’s stock grew similarly to ROCK’s over the last 12 months.
ROCK's Profit vs Risk Rating (78) in the Metal Fabrication industry is in the same range as JAZZ (96) in the Pharmaceuticals Other industry. This means that ROCK’s stock grew similarly to JAZZ’s over the last 12 months.
ROCK's SMR Rating (100) in the Metal Fabrication industry is in the same range as JAZZ (100) in the Pharmaceuticals Other industry. This means that ROCK’s stock grew similarly to JAZZ’s over the last 12 months.
ROCK's Price Growth Rating (49) in the Metal Fabrication industry is in the same range as JAZZ (56) in the Pharmaceuticals Other industry. This means that ROCK’s stock grew similarly to JAZZ’s over the last 12 months.
ROCK's P/E Growth Rating (100) in the Metal Fabrication industry is in the same range as JAZZ (100) in the Pharmaceuticals Other industry. This means that ROCK’s stock grew similarly to JAZZ’s over the last 12 months.
| JAZZ | ROCK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 66% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 65% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 67% |
| Advances ODDS (%) | 1 day ago 61% | 6 days ago 72% |
| Declines ODDS (%) | 9 days ago 56% | 1 day ago 74% |
| BollingerBands ODDS (%) | 1 day ago 76% | 5 days ago 71% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 64% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FFNCX | 13.51 | N/A | N/A |
| Fidelity Advisor Asset Manager 40% C | |||
| MLRRX | 12.13 | N/A | N/A |
| NYLI Winslow Large Cap Growth Class R1 | |||
| NBRRX | 26.31 | N/A | N/A |
| Neuberger Berman M/C Intrinsic Val R3 | |||
| DVRUX | 17.46 | N/A | N/A |
| UBS US Dividend Ruler P | |||
| VLEOX | 59.44 | -1.00 | -1.65% |
| Value Line Small Cap Opportunities Inv | |||